Riskpilot← Back to searchSign inGet full accessORIFARM GENERICS HOLDING A/S
A/SActiveCVR 27347223Energivej 15Activities of holding companies · NACE 6421Est. 20033 employees
Revenue 2024
DKK 243,2M
-26% vs 2023
EBITDA margin
99.1%
-26% vs 2023
Equity ratio
62.1%
Financial strength
Net profit 2024
DKK 89,4M
-3% vs 2023
| Revenue | DKK 243,2M | -26% |
| EBITDA | DKK 240,9M | -26% |
| Net profit | DKK 89,4M | -3% |
| Total assets | DKK 3,4B | -2% |
| Equity | DKK 2,1B | -3% |
| Employees | 3 | — |
Legal name
ORIFARM GENERICS HOLDING A/S
CVR number
27347223
Legal form
Aktieselskab
NACE code
6421 · Activities of holding companies
Founded
12. september 2003
Share capital
DKK 1.300.000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den administrerende direktør og ét bestyrelsesmedlem i forening, af bestyrelsesformanden alene eller af to bestyrelsesmedlemmer i forening.
Company purpose
Selskabets formål er at besidde kapitalandele i datterselskaberne og at erhverve og besidde immaterielle og materielle aktiver, som knytter sig til disse. Endvidere er selskabets formål at forestå forretningsudvikling og ledelsesmæssige opgaver for datterselskaber samt dertil beslægtede opgaver, der måtte forekomme i koncernen.
Address
Energivej 15
Phone
+4563952800
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 12.868 | 190.643 | 309.186 | 326.755 | 243.237 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 12.868 | 190.643 | 309.186 | 326.755 | 240.938 |
| Depreciation & amort. | -9.498 | -79.798 | -103.224 | -143.619 | -150.337 |
| EBIT | 3.370 | 110.845 | 205.962 | 183.136 | 90.601 |
| Net financials | 110.127 | 125.503 | -34.094 | -66.875 | 3.002 |
| Profit before tax | 113.497 | 236.348 | 171.868 | 116.261 | 93.603 |
| Tax | -674 | 23.295 | 41.518 | 24.418 | 4.240 |
| Net profit | 114.171 | 213.053 | 130.350 | 91.843 | 89.363 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 627.598 | 3.214.708 | 3.718.630 | 3.482.474 | 3.421.509 |
| Equity | 417.490 | 2.479.781 | 2.108.078 | 2.187.191 | 2.125.068 |
| Long-term debt | 64.270 | 332.420 | 310.916 | 311.529 | 0 |
| Short-term debt | 138.195 | 297.625 | 1.169.157 | 903.950 | 1.192.001 |
| Total debt | 202.465 | 630.045 | 1.480.073 | 1.215.479 | 1.192.001 |
EBITDA margin
99.1%
This company
15.8%
Market median
+527% vs market
20202024
Equity ratio
62.1%
This company
38.2%
Market median
+63% vs market
20202024
Return on equity
4.2%
This company
18.4%
Market median
-77% vs market
20202024
Net profit margin
36.7%
This company
8.1%
Market median
+353% vs market
20202024
Asset turnover
0.07×
This company
1.12×
Market median
-94% vs market
20202024
Debt / equity
0.61×
This company
0.62×
Market median
+2% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
TB Chief Executive Officer | Chief Executive Officer | 2025 |
| Former (3) | ||
KH Chief Executive Officer | Chief Executive Officer | 2018 – 2019 |
UE Chief Executive Officer | Chief Executive Officer | 2013 – 2018 |
UK Chief Executive Officer | Chief Executive Officer | 2019 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Chairman | 2013 | |
| Board of Directors | 2025 | |
| Board of Directors | 2016 | |
| Board of Directors | 2025 | |
| Former (10) | ||
| Board of Directors | 2015 – 2016 | |
| Board of Directors | 2013 – 2014 | |
| Board of Directors | 2003 – 2006 | |
| Board of Directors | 2013 – 2025 | |
| Board of Directors | 2015 – 2016 | |
| Board of Directors | 2014 – 2016 | |
| Board of Directors | 2013 – 2014 | |
| Board of Directors | 2013 – 2016 | |
| Chairman | 2003 – 2013 | |
| Board of Directors | 2006 – 2007 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2004 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
HABICO A/S
ORIFARM GENERICS HOLDING A/S Board members of ORIFARM GENERICS HOLDING A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Thomas Brandhof | Chief Executive Officer | 0 companies |
| Karsten Haumann | Chief Executive Officer | 0 companies |
| Ulrik Ernst Rasmussen | Chief Executive Officer | 0 companies |
| Ulrik Kronborg Markussen | Chief Executive Officer | 0 companies |
| Rolf Eckersberg | Board of Directors | 0 companies |
| Hans Carl Bøgh-Sørensen | Chairman | 0 companies |
| Jean-Francois Loumeau | Board of Directors | 0 companies |
| Mads Fink Eriksen | Board of Directors | 0 companies |
| Jan Johannes Wøidemann | Board of Directors | 0 companies |
| Erik Sandberg | Board of Directors | 0 companies |
| Claus Christian Bayer | Board of Directors | 0 companies |
| Claudio Albrecht | Board of Directors | 0 companies |
| Birgitte Bøgh-Sørensen | Board of Directors | 0 companies |
| Hans Christian Eberhard Groth Teisen | Board of Directors | 0 companies |
| Peter Arend William Burema | Board of Directors | 0 companies |
| Ole Michael Friis | Chairman | 0 companies |
| Niels Harald de Coninck-Smith | Board of Directors | 0 companies |
| Nicki Lund Kristensen | Board of Directors | 0 companies |